18 March 2020
Biosimilar drugs deemed to be the ‘real deal’ in today’s Biopharmaceutical landscape
In the current financial climate, with National Health Services across Western countries under increasing pressure to ‘do more with less’, biosimilar drugs are starting to attract significant attention and are likely to reshape the pharmaceutical industry as we know it.
